fingolimod hydrochloride has been researched along with Glial Cell Tumors in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aizu-Yokota, E; Hasegawa, M; Kasahara, T; Momoi, T; Sakurai, S; Sonoda, Y; Yamamoto, D | 1 |
1 other study(ies) available for fingolimod hydrochloride and Glial Cell Tumors
| Article | Year |
|---|---|
FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 6; Caspases; Cell Death; Cell Survival; Cysteine Proteinase Inhibitors; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Activation; Etoposide; Fingolimod Hydrochloride; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Glioma; Humans; Immunosuppressive Agents; Oligopeptides; Phosphatidylinositol 3-Kinases; Phosphorylation; Propylene Glycols; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Sphingosine; Time Factors; Tumor Cells, Cultured; Tyrosine; Vanadates | 2001 |